AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01550055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB009 plus Irinotecan
Description: Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
Study NCT01550055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan-only and sequential-CMAB009
Description: First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
Study NCT01237847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Family-based problem solving phone sessions
Description: 2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
Study NCT01237847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Family-based problem solving phone intervention sessions
Description: 4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
Study NCT01237847 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list comparison group
Description: Wait list comparison group to receive intervention at later point.
Study NCT02336256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedures of hernia repair.
Description: We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
Study NCT02336256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedures of hernia repair.
Description: We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
Study NCT00717548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Trauma-Focused short term intervention (8-12 sessions)
Study NCT00406614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-Focused High Blood Pressure Intervention
Description: Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
Study NCT00406614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy-Focused High Blood Pressure Intervention
Description: Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
Study NCT01268124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTC-867
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Study NCT04142411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Ultrasound guided perineural injection therapy (PIT)
Study NCT04142411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Ultrasound guided perineural injection therapy (PIT)
Study NCT04142411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Ultrasound guided perineural injection therapy (PIT)
Study NCT04142411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ultrasound guided perineural injection therapy (PIT)
Study NCT04142411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Philips Neuromuscular Ultrasound
Study NCT04142411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Philips Neuromuscular Ultrasound
Study NCT02977299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
Study NCT02977299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
Study NCT02977299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
Study NCT00803777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Blood Glucose Monitoring System
Description: Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
Study NCT00130845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres
Study NCT00130845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00624910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge (CollaRx®)
Description: The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Study NCT00624910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Study NCT02573272 — intervention group
Intervention type: DRUG
Intervention: eslicarbacepine
Study NCT03376035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement of breast
Description: Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
Study NCT03376035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temperature measurement of breast
Description: Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
Study NCT01898780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy with horizontal mattress suture
Study NCT01898780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy with interrupted suture
Study NCT00960609 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided liver resection
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01289132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
Study NCT03436303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/MP 100mg
Description: CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
Study NCT03436303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/MP 100mg
Description: CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
Study NCT03436303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.625mg/dydrogesterone
Description: CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
Study NCT02246881 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Optivate® (Human Coagulation Factor VIII)
Study NCT02246881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study NCT02432170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis of Foot and Ankle
Description: Imaging Technique
Study NCT01278147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education program
Description: the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
Study NCT04729842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Brachial plexus block
Description: Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
Study NCT01789840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Study NCT01789840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Study NCT00908349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxcarbazepine XR
Description: Open Label Study
Study NCT05328310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
Study NCT05328310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: low dose
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: moderate dose
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Study NCT04551365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Description: Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
Study NCT04551365 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle changes
Description: Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
Study NCT04551365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
Study NCT04551365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
Study NCT02570035 — intervention group
Intervention type: DRUG
Intervention: Mirabegron
Description: oral
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: high dose
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
Study NCT01614106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retention Clinic
Description: The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
Study NCT04375098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: COVID-19 convalescent plasma
Study NCT00427219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozarelix
Description: Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
Study NCT00427219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IM on Day 0 and Day 14.
Study NCT01041677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 10 mg capsule twice daily
Study NCT01041677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule twice daily
Study NCT01041677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 15 mg capsule twice daily
Study NCT02536274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbo Sensa® bandage
Description: Patients have to wear it over 21-28 days for at least 8 hours a day
Study NCT02536274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynaflex® flexion orthosis
Description: Patients have to wear it over 21-28 days for at least 8 hours a day
Study NCT03244267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Education
Description: Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
Study NCT03244267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
Study NCT03244267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Reminder App
Description: Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
Study NCT04498039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Neuromodulation Stimulator
Description: Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
Study NCT04498039 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Portable Neuromodulation Stimulator
Description: Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
Study NCT03865719 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Habits for Life
Description: Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
Study NCT02309723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta amyloid imaging
Study NCT04389307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation (IVES)
Description: IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
Study NCT04389307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bladder Training
Description: Bladder Training
Study NCT04389307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Training
Description: Bladder Training
Study NCT03927326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: Liposomal bupivacaine
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02503826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Study NCT04009629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercise
Description: Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
Study NCT00568841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
Study NCT00568841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-/FLT-PET
Study NCT02760563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
Study NCT00761956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen CR-Flex Fixed Bearing Knee
Description: NexGen CR-Flex Fixed Bearing femoral component
Study NCT00761956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen CR Knee
Description: NexGen Complete Knee Solution Cruciate Retaining femoral component
Study NCT02989090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive Detailed ICD Information-electronic
Description: Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
Study NCT02989090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receive Detailed ICD Information-paper
Description: Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
Study NCT00954005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapy with Rituximab, Gemcitabine and Oxaliplatin
Description: Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
Study NCT03596398 — intervention group
Intervention type: GENETIC
Intervention: GLA gene
Description: Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.